N-{(4R)-4-(4-Methoxyphenyl)-3-[2-(4-methoxyphenyl)ethyl]-2-oxo-1- imidazolidinyl}methanesulfonamide

Names

[ Name ]:
N-{(4R)-4-(4-Methoxyphenyl)-3-[2-(4-methoxyphenyl)ethyl]-2-oxo-1- imidazolidinyl}methanesulfonamide

Biological Activity

[Description]:

KVI-020 is an orally active, potent and selective blocker of the atrial potassium channel Kv1.5, with an IC50 of 480 nM. KVI-020 can inhibits hERG, with an IC50 of 15100 nM. KVI-020 is a potent antiarrhythmic agent, and can be used for atrial fibrillation (AF) research[1].

[Related Catalog]:

Research Areas >> Cardiovascular Disease

Signaling Pathways >> Membrane Transporter/Ion Channel >> Potassium Channel

[Target]

IC50: 480 ± 44 nM (Kv1.5), 15100 nM (hERG)[1]

[References]

[1]. Blass BE, et al. Selective Kv1.5 blockers: development of (R)-1-(methylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(4-methoxyphenyl)-2-imidazolidinone (KVI-020/WYE-160020) as a potential treatment for atrial arrhythmia. J Med Chem. 2009 Nov 12;52(21):6531-4.

Chemical & Physical Properties

[ Molecular Formula ]:
C₂₀H₂₅N₃O₅S

[ Molecular Weight ]:
419.49500

[ Exact Mass ]:
419.15100

[ PSA ]:
96.56000

[ LogP ]:
3.53690